Introduction
The standard of care for the mobilization of stem cells in patients undergoing autologous transplantation involves the use of G-CSFs, usually filgrastim or sargramostim, with or without mobilizing chemotherapy to obtain sufficient numbers of CD34 þ cells to ensure durable engraftment. 1 Currently, the use of pegfilgrastim provides the advantage of a once-per-cycle schedule of administration and a reduction in expense, but it is not believed to reduce the toxicities associated with growth factor administration. 2 The use of growth factors alone without chemotherapy results in a less toxic mobilization procedure, although this regimen often requires a greater number of aphereses because stem cell yield is reduced. 3 The mobilization of stem cells in patients with immunoglobulin light-chain amyloidosis (AL) is associated with unique and substantial toxicities. Dramatic degrees of fluid retention in patients with coexistent cardiac amyloidosis or nephrotic syndrome can result in major delays in subsequent conditioning chemotherapy and have been associated with reported deaths. In one report of six patients, one patient died after stem cell mobilization. 4 A series of 42 patients had a morbidity rate of 50% (21 of 42), and in two patients (5%), the complications were life-threatening. 5 We have reported that an increase of more than 2% of a patient's body weight during stem cell mobilization resulted in a poor outcome after highdose therapy. 6 A weight increase of more than 2% occurred during mobilization in more than half of the patients. Also, the amyloidosis research group at Boston University has noted that edema is a complicating factor in 23% of patients and pulmonary edema was seen in 18% of patients. 7 Splenic rupture during stem cell mobilization in the presence of splenic amyloidosis has been reported. 8 Investigators at Boston University reported two patients in whom splenic rupture developed because of growth factor administration. Presumably, the patients had extensive amyloid deposits in the spleen, rendering the capsule rigid during the expansion of neutrophils after filgrastim therapy. 9 They also reported pulmonary edema developing in 12 of the 75 patients. In one report of 205 patients, 20 were unable to proceed to high-dose therapy because of complications that occurred during mobilization. 10 The high prevalence of growth factor-related complications in patients with AL resulted in the Mayo Clinic program's adoption of a policy of no growth factor administration after day 0 of stem cell infusion. In this paper, we report on the outcomes in a cohort of patients who received high-dose chemotherapy, stem cell infusion and no posttransplantation growth factor. The key endpoints were engraftment, hospitalization and the frequency of bacteremia.
Patients and methods
In our study, 282 consecutive patients received stem cell transplants without receiving growth factor to promote engraftment. No patient was excluded from the analysis. Data of patients who died before engraftment were censored on the date of death, and the patients were considered as not having engraftment and were included. All patients were considered evaluable for bacteremia and duration of hospitalization. Bacteremia was defined as the presence of a positive finding on blood culture at any time during the transplantation course. Surveillance blood cultures were done before day À2 in all patients after catheter placement. The finding of a positive blood culture in a patient who had no symptoms was considered detection of a bacteremia. No attempt was made to distinguish contaminants from known pathogens, and in this immuno-incompetent population, patients with an infection due to micrococcus or corynebacterium were considered to have bacteremia. Eligibility criteria for transplantation included biopsy-verified AL and visceral organ involvement.
Patients with AL who are seen at Mayo Clinic Rochester are prospectively enrolled in a database that has relevant demographic, clinical and laboratory characteristics and is continuously updated. All patients undergoing high-dose therapy for AL through May 2006 are included in this paper. No patients were excluded, and no patients have been lost to follow-up. Patients gave written consent in accordance with Minnesota laws, Mayo Clinic Institutional Review Board regulations and appropriate federal regulations. Engraftment was calculated from day 0 of the stem cell transplantation. Neutrophil engraftment required a sustained count of 500 neutrophils per ml. Engraftment of 20 000 and 50 000 platelets per ml required that the platelet count be sustained with no platelet transfusions in the antecedent 48 h.
The Kaplan-Meier method was used for the analysis of time to engraftment. Analysis of group differences for continuous variables was performed using the KruskalWallis test. The baseline evaluation of all patients being considered for stem cell transplantation included creatinine clearance and echocardiography. Patients' conditioning regimen was based on their risk of toxicity after high-dose therapy. Melphalan chemotherapy was given over 2 consecutive days.
All patients who received a transplant had a minimum of 2 Â 10 6 CD34 þ cells/kg, although our target level was 4 Â 10 6 CD34 þ cells/kg. In an attempt to achieve these levels, apheresis was continued. Apheresis was performed by processing 11-14 l of blood in 4 h. 11 In 36 patients, stem cells were mobilized using cyclophosphamide and sargramostim; 246 patients received filgrastim only.
Standard posttransplantation supportive care was administered, including the use of prophylactic fluoroquinolone antibiotics and fluconazole. All patients were treated and received conditioning chemotherapy and stem cell infusions as outpatients. Patients who had persistent neutropenic fever, intractable mucositis, dehydration or a decline in performance status were hospitalized.
Results
The characteristics of the patients in this study are listed in Table 1 . Figures 1-3 illustrate time-to-engraftment curves.
A neutrophil count of 500/ml was achieved in 50, 75 and 90% of patients at 14, 16 and 22 days, respectively ( Figure 1) . A platelet count of 20 000/ml was achieved in 50, 75 and 90% of patients at 14, 20 and 31 days, respectively ( Figure 2) . A platelet count of 50 000/ml was achieved in 50, 75 and 90% of patients at 19, 29, and 82 Table 1 Characteristics of patients in the study (N ¼ 282) days, respectively ( Figure 3 ). Of note, one patient did not achieve a platelet count of 50 000/ml until day 923. Among the 28 patients who had a CD34 þ infusion of 3.0 Â 10 6 cells or fewer, the median time to neutrophil engraftment was 14 days; 75% achieved engraftment by 19 days, and all patients achieved engraftment by 38 days. Patients who had more than 3.0 Â 10 6 stem cells collected also had a median of 14 days to neutrophil engraftment, but 75% achieved engraftment by 16 days, 3 days fewer than in the patients with an infusion of a lower stem cell count (P40.2).
Patients who received an infusion of 3.0 Â 10 6 CD34 þ cells or fewer achieved a level of 20 000 platelets/ml at a median of 25 days; 75% achieved this level in 33 days. Patients who received this infusion count achieved a level of 50 000 platelets/ml at a median of 33 days; 75% achieved it in 70 days. By comparison, patients who received an infusion of more than 3.0 Â 10 6 CD34 þ cells achieved a level of 20 000 platelets/ml at a median of 14 days (11 days earlier than the first group); 75% achieved this level in 19 days (P ¼ 0.002). This second group of patients achieved a level of 50 000 platelets/ml at a median of 18 days (15 days earlier than the first group), with 75% achieving this level in 27 days (Po0.001).
Hospitalization and infections
For the entire cohort, the median time spent in the hospital was 9 days, and 75 and 90% of the patients were discharged after 17 and 32 days, respectively. Fifty patients (18%) completed the transplantation cycle without requiring hospitalization. Patients who received 3.0 Â 10 6 CD34 þ cells or fewer had a median hospital stay of 11.5 days; patients who received more than 3.0 Â 10 6 CD34 þ cells had a median stay of 8 days (P40.5). Bacteremia was documented in 126 patients (45%). A total of 80 patients in the transplantation cohort (28% of all patients) had coagulase-negative staphylococcal bacteremia. All other bacteremias occurred in 16% of the patient population.
Although no contemporaneous control group of patients with AL exists, the Mayo Clinic Multiple Myeloma Database includes more than 750 patients who had stem cell transplants and routinely received filgrastim therapy (5 mg/kg 2 per day) beginning on day 5 after transplantation and continuing until sustained engraftment. In a patient with myeloma, the time to a neutrophil count of 500/ml is 13 days, which is 1 day fewer than in the amyloidosis cohort. The patient's time to achieve a platelet count of 50 000/ml is 15 days, which is 4 days fewer than in the amyloidosis cohort.
Discussion
The reported toxicities of growth factor administration to patients without amyloid typically include fatigue, bone pain and low-grade fever. Fluid retention is not mentioned as a side effect. 12, 13 However, our experience with growth factor mobilization in patients with AL was quite different. Among these patients, 52% experienced a weight gain of greater than 2% during mobilization, and the median weight gain during mobilization of all patients exceeded 2.25%. 6 This extent of weight gain was challenging in the cohort of patients, 47% of whom had cardiac amyloidosis. We also demonstrated that diuretic use at baseline and diuretic dose adjustments were more common in patients who gained weight. These findings led to the decision to withhold growth factor administration in patients with AL.
The current study showed the feasibility of transplantation without the use of growth factors to promote engraftment in patients who have AL. In an analysis of the factors that predict engraftment, a report on 225 patients cited neutropenia of 10 days' duration and showed that the CD34 þ stem cell dose, the sex of the patient and previous therapy with an alkylating agent all delayed engraftment.
14 The median time of gaining a platelet count of more than 20 000/ml was 13 days, and preserved renal function in the absence of fever predicted a prompt platelet engraftment.
In a prospective, randomized controlled study using filgrastim in patients with lymphoma who were undergoing autologous bone marrow transplantation, the median time to neutrophil engraftment in the filgrastim group was 10 days compared with 14 days in the control group, a 4-day improvement. 15 Other studies have shown a clear economic benefit to the use of filgrastim, but this benefit has been demonstrated in a cohort of patients who do not have the unique fluid-retention problems that patients with AL have. Because our study was not designed as a pharmacoeconomic analysis, it is not possible to say whether the fluid-retention complications result in increased hospitalization that offsets any monetary savings of growth factor administration.
In more than 500 patients with myeloma, the median time to attain a neutrophil count of 500/ml was 13 days when the infusion dose was a CD34
þ count of more than 3.0 Â 10 6 , compared with 14 days when the CD34 þ count was 3.0 Â 10 6 or less. Platelet levels greater than 20 000/ml were seen at 10 days when the infusion dose was a CD34 þ count of more than 3.0 Â 10 6 and at 12 days when the CD34 þ count was 3.0 Â 10 6 or less. The number of transplanted CD34
þ cells had no effect on the rate of mortality or overall survival. 16 In this cohort, no patients received G-CSF after high-dose chemotherapy and transplantation, which is the customary regimen in Europe. In our study, the infusion of more than 3.0 Â 10 6 CD34 þ cells appeared to have at least as much effect on engraftment times as the use of filgrastim after transplantation.
Infections after peripheral blood progenitor cell transplantation for lymphoma have been extensively studied. They have been documented in approximately 30% of patients; bacteremia has been documented in 25% of patients. Primary bacteremia was reported in 25 (21%) of 117 patients who received a transplantation; the cases included three fatal infections. 17 In a study of infectious complications in patients with multiple myeloma who were receiving high-dose therapy, primary bacteremia was seen in 21.3%. 18 Fatal infections occurred in 2.6%. A second study reported that infections were documented in 30% of patients with myeloma after peripheral blood progenitor cell transplantation. 17 Infectious complications from a single institution study were 39%, with Gram-positive cocci being the predominant pathogens-an incidence rate comparable to the results reported herein. 19 Among the 156 Mayo Clinic patients in the current study who did not have bacteremia, eight died within the first month (5%) (A total of 20 patients died within the first month of receiving the transplantation. In the 11 patients who had bacteremia, one infection was related to graft failure and three were coagulase-negative staphylococcal bacteremia). Among the 126 patients with bacteremia who survived beyond 1 month, seven bacteremias were connected with the death of the patient (6%, a difference that is not statistically significant). Our definition of bacteremia may in part account for the relatively high incidence of infections that we report.
In this study, we showed that it is feasible and reasonable to withhold growth factor administration after transplantation. This practice is the custom in many of the European countries that perform stem cell transplantation. 20, 21 Other investigators have also questioned whether postinfusion G-CSF administration has a clear financial benefit. 22 We demonstrated that in amyloidosis, it is also possible to perform stem cell transplantation as an outpatient procedure; however, the majority of patients who receive the transplant do require hospitalization (the median stay is 9 days). In 1 study, the median hospitalization duration was 25 days for patients with renal impairment. 23 We also showed that although bacteremia occurs frequently, it does not appear to be directly related to the duration of neutropenia because most of the bacteremia is related to an indwelling central catheter by skin contamination with coagulase-negative Staphylococcus. The prevalence of bacteremia in these patients does not appear to be connected with the risk of death, which in the majority of our patients appeared to be due to multiorgan failure precipitated by the conditioning of the patients, who had pre-existent organ dysfunction due to amyloidosis.
We conclude that growth factor administration is not required for an adequate outcome after stem cell transplantation. We believe that withholding growth factor therapy reduces the number and severity of some of the fluid-related complications after transplantation without compromising care and results in a likely decrease in the overall cost of transplantation.
